Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

Fig. 1

PRISMA diagram. aMixed chemotherapy regimens which included both Q2W and Q3W studies without prophylactic pegfilgrastim (or patients received both Q2W and Q3W regimens) were excluded. bThe literature search included all relevant studies from January 1, 2002 through June 30, 2019. Any study before 2002 was then excluded. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Q2W biweekly, Q3W every 3 weeks

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us